Interestingly, a fraction of the both ccRCC and ChRCC (~20%) show alterations impacting the PTEN/MTOR pathway with the greatest number of mutations in ChRCC being present within the PTEN gene. The gene discussed is MTOR; the disease is chromophobe renal cell carcinoma.